Paris – 28.05.2026: In a significant step for the treatment of obesity in France, Health Minister Stéphanie Rist announced today that the drugs Wegovy and Mounjaro are now reimbursable. This decision marks an important milestone in the fight against obesity, which affects over eight million people in France.
Wegovy, a drug from the Danish pharmaceutical company Novo Nordisk, was not reimbursed in France since its introduction in October 2024, and patients paid between 274 and 365 euros per month. With the new reimbursement policy, the price for the first three doses is set at 146.91 euros per month, significantly reducing costs for patients.
The decision to reimburse Wegovy and Mounjaro was made after intensive negotiations between the French Ministry of Health and the manufacturers. These discussions focused on establishing a fair price and defining reimbursement through the medical insurance legislative system. Although the exact details of the agreement have not yet been disclosed, reimbursement is expected to take effect in the second half of 2026.
The reimbursement of these drugs will have a significant impact on obesity treatment in France. Experts estimate that annual reimbursement costs will reach around 100 million euros. These investments are considered necessary to overcome rising healthcare costs associated with obesity, as well as to improve patients’ quality of life.
Novo Nordisk welcomed the French government’s decision and emphasized that the reimbursement of Wegovy is an important step in the fight against obesity. Additionally, the company announced a price reduction of Wegovy in France to 146.91 euros per month for the first three doses to increase the accessibility of the drug.
Experts in healthcare view the introduction of reimbursement for Wegovy and Mounjaro as a move in the right direction for improving obesity treatment in France. However, it is emphasized that a comprehensive strategy is needed that, in addition to drug therapy, includes preventive measures and improvement of the population’s dietary habits.
The French government plans to conduct broad public information campaigns in the coming weeks about the reimbursement details and prescription conditions for Wegovy and Mounjaro. Patients interested in treatment with these drugs are advised to consult their family doctor or specialist to get additional information and discuss the most appropriate therapy options.
The decision to reimburse Wegovy and Mounjaro in France is seen as an important step in combating obesity and may become a model for other European countries facing similar challenges. It remains to be seen what impact this decision will have on the prevalence of obesity and associated healthcare costs in France.
Dieser Artikel wurde mit Hilfe künstlicher Intelligenz erstellt.